Checkmate Pharmaceuticals is investigating vidutolimod (CMP-001) across multiple tumor types in combination with checkpoint inhibitor immunotherapies in melanoma and non-melanoma skin cancers and head and neck cancer. Vidutolimod’s growing body of promising clinical data demonstrates its potential to address the unmet need for patients whose cancers are resistant to immunotherapeutic agents.

Scroll to Top